New article out this morning on EXEL. I'll have to reread it a few times, but it sure seemed solid!
Agreed, very good article. I think it shed's light on the different targeted pathways between the two drugs and why cabozantinib outshines tivantinib....hands down!
Agreed. I'm more bullish than ever and wish I had bought more down lower. I'll add more Monday now and sell half on the way up and maybe hold half through the PDUFA date (but will probably be surprised by an early approval). Good luck!